卡氮芥（NSC - 409962）在晚期霍奇金病治疗中的作用：其在诱导缓解和维持治疗中的角色。
BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
作者信息
Anderson T, DeVita T, Young R C
出版信息
Cancer Treat Rep. 1976 Jun;60(6):761-7.
BCNU is an effective antitumor agent in the treatment of Hodgkin's disease. Forty-seven percent of a group of patients with advanced disease, refractory to combination or sequential-agent chemotherapy, achieved an objective response to BCNU. Bone marrow toxicity was delayed in onset and was dose related. When incorporated into a maintenance program after remission induction with combination chemotherapy, BCNU appeared to delay, but not ultimately prevent, relapses during a 2-year followup period. Toxic effects associated with BCNU maintenance therapy in this clinical situation were significantly greater than toxic effects associated with no maintenance therapy.
卡莫司汀是治疗霍奇金病的一种有效抗肿瘤药物。一组晚期疾病患者，对联合化疗或序贯化疗耐药，其中47%对卡莫司汀有客观反应。骨髓毒性起病延迟且与剂量相关。在联合化疗诱导缓解后纳入维持方案时，卡莫司汀在2年随访期内似乎延迟了复发，但最终未能预防复发。在这种临床情况下，与卡莫司汀维持治疗相关的毒性作用明显大于与不进行维持治疗相关的毒性作用。
Zotero 插件